Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 10/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.37 |
| ▸ | CFTR | P13569 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23677166 | 0.90 | SSTR4 (0.41) | SCN9ASSTR4MAPK1AAK1CYP1A2 | |
| SCHEMBL17247992 | 0.84 | MAPK1 (0.43) | SCN9ASSTR4MAPK1AAK1CFTR | |
| SCHEMBL17428846 | 0.84 | SSTR4 (0.45) | SCN9ASSTR4AAK1CYP1A2CYP3A4 | |
| SCHEMBL23677235 | 0.84 | SSTR4 (0.40) | SCN9ASSTR4AAK1 | |
| SCHEMBL15599218 | 0.83 | SSTR4 (0.47) | SSTR4AAK1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL15599257 | 0.82 | MAPK1 (0.43) | SCN9AMAPK1AAK1CFTR | |
| SCHEMBL17244897 | 0.82 | SCN9A (0.42) | SCN9AMAPK1AAK1 | |
| SCHEMBL23677211 | 0.82 | SCN9A (0.49) | SCN9AMAPK1CFTRCYP1A2CYP3A4 | |
| SCHEMBL19075640 | 0.82 | SCN9A (0.42) | SCN9AMAPK1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL17248007 | 0.82 | SSTR4 (0.46) | SCN9ASSTR4MAPK1AAK1CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3854782-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3166939-B1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-2970156-B1 | SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017172802-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-10-05 | — | — | WO | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| WO-2014008458-A2 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | SCN9A 2337/4885SSTR4 1035/4885MAPK1 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.